HK1255330A1 - 适用於治疗与ntrk相关的病症的化合物和组合物 - Google Patents

适用於治疗与ntrk相关的病症的化合物和组合物 Download PDF

Info

Publication number
HK1255330A1
HK1255330A1 HK18114466.6A HK18114466A HK1255330A1 HK 1255330 A1 HK1255330 A1 HK 1255330A1 HK 18114466 A HK18114466 A HK 18114466A HK 1255330 A1 HK1255330 A1 HK 1255330A1
Authority
HK
Hong Kong
Prior art keywords
ring
mixture
compound
cycloalkyl
tert
Prior art date
Application number
HK18114466.6A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文‧M‧翁劳斯基
史蒂文‧M‧翁勞斯基
娜塔莎‧布鲁杰孟
昌德拉塞卡．V．曼德拉
娜塔莎‧布魯杰孟
尼尔．比富尔科
尼爾．比富爾科
Original Assignee
缆图药品公司
藍圖藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 缆图药品公司, 藍圖藥品公司 filed Critical 缆图药品公司
Publication of HK1255330A1 publication Critical patent/HK1255330A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18114466.6A 2015-08-26 2016-08-25 适用於治疗与ntrk相关的病症的化合物和组合物 HK1255330A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210264P 2015-08-26 2015-08-26
US62/210,264 2015-08-26
PCT/US2016/048698 WO2017035354A1 (en) 2015-08-26 2016-08-25 Compounds and compositions useful for treating disorders related to ntrk

Publications (1)

Publication Number Publication Date
HK1255330A1 true HK1255330A1 (zh) 2019-08-16

Family

ID=56896780

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114466.6A HK1255330A1 (zh) 2015-08-26 2016-08-25 适用於治疗与ntrk相关的病症的化合物和组合物

Country Status (17)

Country Link
US (2) US10017512B2 (https=)
EP (1) EP3341374A1 (https=)
JP (1) JP6877407B2 (https=)
KR (1) KR20180043810A (https=)
CN (1) CN108137607B (https=)
AR (1) AR105836A1 (https=)
AU (1) AU2016311426B2 (https=)
BR (1) BR112018003588A2 (https=)
CA (1) CA2995997A1 (https=)
HK (1) HK1255330A1 (https=)
IL (1) IL257702A (https=)
MX (1) MX2018002407A (https=)
PH (1) PH12018500397A1 (https=)
RU (1) RU2744974C2 (https=)
TW (1) TW201713665A (https=)
WO (1) WO2017035354A1 (https=)
ZA (1) ZA201801881B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
CA2928042C (en) 2013-10-25 2022-05-10 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
WO2017019442A1 (en) 2015-07-24 2017-02-02 Blueprint Medicines Corporation Compounds useful for treating disorders related to kit and pdgfr
AU2016311426B2 (en) 2015-08-26 2021-05-20 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
PL3371171T3 (pl) 2015-11-02 2024-03-25 Blueprint Medicines Corporation Inhibitory RET
MX2018006195A (es) 2015-11-19 2018-09-05 Blueprint Medicines Corp Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ｒｅｔ之抑制劑
SG11201808907PA (en) 2016-04-15 2018-11-29 Blueprint Medicines Corp Inhibitors of activin receptor-like kinase
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
DK3674307T3 (da) 2017-08-23 2023-09-11 Chia Tai Tianqing Pharmaceutical Group Co Ltd Makrocyklus indeholdende aminopyrazol og pyrimidin og farmaceutisk sammensætning og anvendelse deraf
WO2019079649A1 (en) 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
WO2019152982A1 (en) * 2018-02-05 2019-08-08 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic compounds as ep4 antagonists
BR112020019399A2 (pt) * 2018-03-28 2021-01-05 Fochon Pharmaceuticals, Ltd. Compostos macrocíclicos como inibidores de trk quinases
SI3773589T1 (sl) 2018-04-03 2024-03-29 Blueprint Medicines Corporation Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo
MX2021010173A (es) * 2019-02-27 2021-12-10 Ferro Therapeutics Inc Compuestos con actividad inductora de ferroptosis y métodos de uso.
WO2020210669A1 (en) 2019-04-12 2020-10-15 Blueprint Medicines Corporation Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
EP4065585B1 (en) * 2019-11-25 2025-08-20 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP2023527412A (ja) 2020-05-29 2023-06-28 ブループリント メディシンズ コーポレイション プラルセチニブの固体形態
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251911B1 (en) * 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
PT1537116E (pt) 2002-09-04 2010-09-03 Schering Corp Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
TWI378934B (en) * 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2566866A1 (en) * 2010-05-05 2013-03-13 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
CA2882759C (en) * 2012-08-31 2018-11-20 The Regents Of The University Of Colorado Detection of the ntrk1-mprip gene fusion for cancer diagnosis
KR20150072412A (ko) 2012-10-05 2015-06-29 리겔 파마슈티칼스, 인크. Gdf-8 억제제
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
JP2016506944A (ja) * 2013-02-01 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロピリミジニルアミノ−インダゾール
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
MX2015010700A (es) 2013-02-21 2017-01-23 Calitor Sciences Llc Compuestos heteroaromaticos como moduladores de la p13 cinasa.
WO2014139326A1 (en) 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
CA2928042C (en) 2013-10-25 2022-05-10 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
CN106536507B (zh) 2014-04-08 2020-04-07 里格尔药品股份有限公司 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
CA2971024C (en) 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CN107531666A (zh) 2015-02-20 2018-01-02 里格尔药品股份有限公司 Gdf‑8抑制剂
WO2017019442A1 (en) 2015-07-24 2017-02-02 Blueprint Medicines Corporation Compounds useful for treating disorders related to kit and pdgfr
AU2016311426B2 (en) 2015-08-26 2021-05-20 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
PL3371171T3 (pl) 2015-11-02 2024-03-25 Blueprint Medicines Corporation Inhibitory RET
MX2018006195A (es) 2015-11-19 2018-09-05 Blueprint Medicines Corp Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ｒｅｔ之抑制劑
SG11201808907PA (en) 2016-04-15 2018-11-29 Blueprint Medicines Corp Inhibitors of activin receptor-like kinase
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Also Published As

Publication number Publication date
KR20180043810A (ko) 2018-04-30
PH12018500397A1 (en) 2018-08-29
AU2016311426A1 (en) 2018-04-05
US10017512B2 (en) 2018-07-10
RU2744974C2 (ru) 2021-03-17
ZA201801881B (en) 2019-05-29
WO2017035354A1 (en) 2017-03-02
CA2995997A1 (en) 2017-03-02
US20170066773A1 (en) 2017-03-09
AU2016311426B2 (en) 2021-05-20
RU2018110379A3 (https=) 2019-12-26
US20190169194A1 (en) 2019-06-06
AR105836A1 (es) 2017-11-15
JP6877407B2 (ja) 2021-05-26
TW201713665A (zh) 2017-04-16
CN108137607A (zh) 2018-06-08
MX2018002407A (es) 2018-11-29
EP3341374A1 (en) 2018-07-04
IL257702A (en) 2018-04-30
BR112018003588A2 (pt) 2018-09-25
US11046697B2 (en) 2021-06-29
RU2018110379A (ru) 2019-09-27
JP2018528200A (ja) 2018-09-27
CN108137607B (zh) 2021-04-06

Similar Documents

Publication Publication Date Title
CN108137607B (zh) 适用于治疗与ntrk相关的病症的化合物和组合物
US12595265B2 (en) Inhibitors of activin receptor-like kinase
TWI733713B (zh) 用於治療神經促進性酪氨酸受體激酶相關之異常的化合物與組成物
CN115192577A (zh) Kras突变蛋白抑制剂
WO2024178304A1 (en) Kras modulators
KR102713058B1 (ko) 히스톤 아세틸라제 p300 억제제 및 그 용도
CN110156813A (zh) 作为trk抑制剂的杂环化合物
CN115867346A (zh) 激酶抑制剂
KR20250022815A (ko) Hpk1 억제제 및 이의 의약품에서의 응용
HK40119973A (zh) 用於治疗疾病的稠合环kras抑制剂
HK40065459A (en) Kras mutant protein inhibitors
BR122024013896A2 (pt) Compostos de benzamidas derivados de pirazolil-amino-pirimidinila e seus usos, composição farmacêutica dos mesmos, e forma de dosagem unitária compreendendo a mesma
HK40003732B (zh) 激活素受体样激酶抑制剂